Literature DB >> 28238523

Posterior reversible encephalopathy syndrome (PRES) with sub-arachnoid haemorrhage after bevacizumab and 5-FU.

Jennifer Massey1.   

Abstract

PRES is a neurological syndrome characterised by reversible subcortical vasogenic brain oedema in patients with acute neurological signs and symptoms. It occurs in the context of fluctuations in blood pressure, renal failure, autoimmune disorders, eclamptic syndromes and with use of cytotoxic drugs. We present the case of a 60year old female with advanced bowel cancer who was admitted with seizures and sub-arachnoid haemorrhage, with radiographic features of PRES, shortly after receiving bevacizumab (Avastin), a VEGF-inhibitor. Crown
Copyright © 2017. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bevacizumab; Hypertension; PRES; Seizures

Mesh:

Substances:

Year:  2017        PMID: 28238523     DOI: 10.1016/j.jocn.2017.01.005

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  2 in total

Review 1.  Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology.

Authors:  Chandler Gill; Stasia Rouse; Ryan D Jacobson
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-17       Impact factor: 5.081

2.  Reversible posterior leukoencephalopathy syndrome induced by apatinib: a case report and literature review.

Authors:  Xutong Li; Jie Chai; Zhi Wang; Lin Lu; Qingye Zhao; Jie Zhou; Fang Ju
Journal:  Onco Targets Ther       Date:  2018-07-30       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.